Arsenic trioxide
- Generic Name
- Arsenic trioxide
- Brand Names
- Trisenox, Arsenic trioxide Accord, Arsenic trioxide Mylan, Arsenic trioxide medac
- Drug Type
- Small Molecule
- Chemical Formula
- As2O3
- CAS Number
- 1327-53-3
- Unique Ingredient Identifier
- S7V92P67HO
- Background
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredo...
- Indication
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
- Associated Conditions
- Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia, Relapsed Acute Promyelocytic Leukemia
- Associated Therapies
- -
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 50
- Registration Number
- NCT00275067
- Locations
- 🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸Edward Cancer Center, Naperville, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00274820
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00258245
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 60
- Registration Number
- NCT00251511
- Locations
- 🇺🇸
Veeda Oncology, Houston, Texas, United States
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00234000
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00227682
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Oncology Specialties, Alabama
- Registration Number
- NCT00225992
- Locations
- 🇺🇸
Comprehensive Cancer Institute, Huntsville, Alabama, United States
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-23
- Lead Sponsor
- German AML Cooperative Group
- Target Recruit Count
- 30
- Registration Number
- NCT00196768
- Locations
- 🇩🇪
Eva Lengfelder, MD, PhD, Mannheim, Germany
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-10
- Target Recruit Count
- 12
- Registration Number
- NCT00201695
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193518
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.